Please assess the completion status of the following clinical trial:

Trial Title: Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 65 or older (must have reached 65th birthday)~* Morphologically confirmed diagnosis of AML, excluding AML-M3~* Must have a Zubrod performance status of 0-3~Exclusion Criteria:~* Patients with known HIV infection are excluded. If HIV infection is suspected based on clinical condition, testing may be performed at the discretion of treatment team, but is not mandated prior to enrollment.~* Patients with central nervous system involvement by AML are excluded~* Patients with history of an active cancer (except basal cell and squamous cell cancers of the skin) within the previous 2 years are excluded

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Drug Treatment (Type: EXPERIMENTAL): Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV

Based on this trial design, predict the completion outcome and termination type (if applicable).